Cardiac Resynchronization Therapy Market Size, Share, Trends And Forecast 2030
The global cardiac resynchronization therapy market size is anticipated to reach USD 10.9 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a lucrative CAGR of 7.3% over the forecast period. The key factors driving the market include constant product advancements, growing initiatives by key companies, and increasing product adoption by end-users. The market was significantly impacted by the COVID-19 pandemic. Some of the major impacts of the pandemic on the market include supply chain disruptions, fall in sales, demand slowdown due to cancellation of elective procedures, and operational hurdles. For instance, Abbott, a market leader in the cardiac rhythm management device industry, reported a decline in revenue growth of the cardiovascular business in 2020.
Boston Scientific also reported a decline
in sales growth across all regions in 2020. By Q3 2021, the company’s sales
recovered gradually with the cardiac rhythm management segment accounting for
USD 1.5 billion in total revenue. Medtronic also reported a negative impact of
the COVID-19 pandemic on its fourth-quarter financial results ending April 24,
2020. The company was impacted by postponed elective and semi-elective
procedures that use Medtronic products. The reluctance of people to undergo
non-COVID-19 emergency procedures affected the company’s emergent product
lines. However, by 2021, the company returned to positive sales growth.
Its cardiac & rhythm management
portfolio sales grew by 11% during a 6-month year-on-year period ending in
October 2021. Constant product advancements and initiatives by key market players
are expected to propel market growth in the coming years. For instance, in May
2017, Medtronic received FDA clearance for its MR-Conditional Quadripolar
CRT-Ps. This extended the company’s lineup. In April 2018, MicroPort acquired
the cardiac rhythm management portfolio from LivaNova PLC, including Platinum
CRT-Ds and Reply CRT-Ps. This established MicroPort CRM as the fifth-largest
CRM business globally. In addition, the company strengthened its market
position by becoming the market leader in the CRM segment in China.
Request Free Sample Report: https://www.grandviewresearch.com/industry-analysis/cardiac-resynchronization-therapy-devices-market
Cardiac
Resynchronization Therapy Market Report Highlights
·
Rapid technological advancements are among
the key trends driving market growth. Increasing geriatric population,
sedentary lifestyles, and rapidly increasing prevalence of Cardiovascular
Diseases (CVDs) are also stimulating the market growth
·
The CRT-D product segment dominated the
market in 2021 owing to the high adoption and wider application scope of these
devices
·
The CRT-P segment is projected to grow at
the fastest CAGR over the forecast period owing to the growing indications and
high prevalence of heart failure across the globe
·
The hospital end-user segment held the
largest market share in 2021 as these facilities are the main point of care for
CRT device implantation post-diagnosis
·
Furthermore, hospitals offer multiple
reimbursement facilities for surgery, consultation, treatment, and more, thus
driving the product adoption and leading to a higher footfall of patients
Key Companies &
Market Share Insights
Competition in the market is expected to be moderate during the
forecast period. The top 5 companies take up approximately 90% of market
shares. In addition, these companies have extensive resources, market
expertise, distribution network, and are involved in deploying strategic
initiatives to increase market share and profits. These strategies include
mergers & acquisitions, geographic expansion, partnerships, the launch of
new products, and R&D activities. Some of the key players in the global cardiac
resynchronization therapy market include: Medtronic, Abbott, Boston Scientific
Corp., Biotronik SE & Co. KG, MicroPort Scientific Corp.
Comments
Post a Comment